Loading organizations...
Boomerang Medical is a Mountain View, California-based bioelectronic medicine company developing neuromodulation technology to treat autoimmune diseases by managing inflammation through the peripheral nervous system. The clinical-stage medical technology startup is currently advancing clinical studies with an initial therapeutic focus on treating patients with Inflammatory Bowel Disease. The organization has raised a total of $18 million in venture capital, comprising a $3 million seed round in 2021 and a $15 million Series A financing in 2022. These financing rounds were backed by notable lead investors Arboretum Ventures and Hatteras Venture Partners to support a growing workforce of approximately 10 employees. Under the leadership of Chief Executive Officer Heather Simonsen, the enterprise recently completed a key patient enrollment milestone in its primary neuromodulation clinical study. Boomerang Medical was established by founder David Miller.
Boomerang Medical has raised $35.0M across 2 funding rounds.
Boomerang Medical has raised $35.0M in total across 2 funding rounds.
Boomerang Medical has raised $35.0M in total across 2 funding rounds.
Boomerang Medical's investors include Arboretum Ventures, Hatteras Venture Partners, Broadview Ventures.
Boomerang Medical is a women-led, clinical-stage bioelectronic medicine company developing implantable neuromodulation technology to treat autoimmune diseases, primarily inflammatory bowel disease (IBD) like Crohn's disease and ulcerative colitis.[1][2][3] The company serves IBD patients facing debilitating symptoms unresponsive to medications or surgery, solving the problem of chronic inflammation by harnessing the body's peripheral nerves to modulate immune responses without drugs.[1][5][7] Its FDA Breakthrough Device Designation and ongoing pivotal trial (BOOM-IBD2) signal strong growth, bolstered by $20M Series B funding in 2025 (total funding ~$38M including prior $18M Series A), successful pilot study completion, and backing from Arboretum Ventures and Hatteras Venture Partners.[3][4][6][7]
Headquartered in Mountain View, California, on El Camino Hospital's campus and as a Fogarty Innovation resident, Boomerang is advancing sacral neuromodulation—an implanted device delivering gentle nerve stimulation with a proven safety record from over 500,000 procedures in other conditions.[1][5][7]
Boomerang Medical emerged around 2021 as a response to the rising global incidence of IBD, a debilitating autoimmune condition affecting millions and impacting quality of life beyond physical health.[1][4][5] Founded by a women-led team, including CEO Heather Simonsen, the company was inspired by bioelectronic medicine's potential to leverage the body's innate "peripheral wiring" for inflammation control, moving beyond drugs and surgery.[2][3][7] Early milestones included FDA Investigational Device Exemption (IDE) approval in April 2022 for an early feasibility study, Breakthrough Device Designation for Crohn's and ulcerative colitis, and first patient enrollments in a multi-center U.S. trial at leading IBD centers.[3][5] Backed initially by Arboretum Ventures (led by Tom Shehab, MD) and Hatteras Venture Partners, it progressed to complete a 40-patient pilot (BOOM-IBD) by 2025, paving the way for the pivotal BOOM-IBD2 trial (NCT06571669).[6][7]
Boomerang rides the bioelectronic medicine wave, shifting autoimmune treatment from pharmaceuticals to device-based neuromodulation amid rising IBD prevalence (up significantly in 15 years) and limitations of current therapies.[1][5][7] Timing aligns with FDA's push for breakthroughs in unmet needs, as no device options exist for ulcerative colitis despite millions affected in the U.S./Europe.[7] Favorable market forces include proven neuromodulation efficacy in adjacent fields (e.g., overactive bladder) and investor appetite for non-drug alternatives amid biologics' high costs/side effects.[7] By pioneering the first U.S. multicenter prospective IBD neuromodulation study, Boomerang influences the ecosystem, promoting awareness via Crohn's & Colitis Foundation membership and validating bioelectronics for broader autoimmune applications.[1][6]
Boomerang Medical is primed for pivotal trial readouts from BOOM-IBD2 (enrolling now), potentially yielding the first neuromodulation approval for IBD and expanding to Crohn's.[6][7] Trends like AI-optimized implants, personalized medicine, and bioelectronics' growth (projected multi-billion market) will accelerate its path, especially with strong VC support and FDA fast-tracking.[3][7] Influence may evolve from pioneer to category leader, disrupting $15B+ IBD market and inspiring women-led medtech innovation—echoing its mission to rewire autoimmune care from within.[1][4]
Boomerang Medical has raised $35.0M across 2 funding rounds. Most recently, it raised $20.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $20M Series B | Arboretum Ventures, Hatteras Venture Partners | Broadview Ventures | Announced |
| Oct 1, 2022 | $15M Series A | Arboretum Ventures, Hatteras Venture Partners | Broadview Ventures | Announced |
